Search Results

Artios Pharma Limited, The University of Texas MD Anderson Cancer Center and ShangPharma Innovation announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.

Under the new deal, Artios Pharma licensed rights to research, develop, manufacture and commercialize products globally from a small-molecule ATR inhibitor program that was jointly developed by MD Anderson and ShangPharma.

ShangPharma announced the appointment of Dirk G. Brockstedt, Ph.D., and Benson Tsang, MBA, to its Executive-In-Residence (EIR) team.

In March venture capital firm ShangPharma Innovations announced its plans to expand its life sciences incubator in San Francisco by 40 percent, including state-of-the-art laboratory infrastructure upgrades to its facility. That investment is paying off as the incubator is growing.

Under the terms of the agreement, ShangPharma Innovation will provide funding and preclinical research support to further ISMMS’s objectives of validating drug targets and establishing programs to discover new therapies.

ShangPharma Innovation Inc., a global venture capital firm focused on filling the critical investment gap that exists for the earliest-stage therapeutic breakthroughs, has expanded its life science incubator by nearly 40 percent and updated the facility with additional state-of-the-art laboratory infrastructure and conferencing space.